The first trial of a novel strategy for removing cholesterol from patients' arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at ...
Apr 8, 2024
0
1
Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels ...
Apr 8, 2024
0
0
A new system that uses dehydrated alcohol to deactivate certain nerves surrounding the kidneys' arteries in order to control high blood pressure met its primary endpoint—lowering blood pressure at three months as measured ...
Apr 8, 2024
0
0
In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of 74% after 24 weeks of use without causing ...
Apr 8, 2024
0
0
People with high blood pressure saw their systolic blood pressure drop by 7 mmHg, on average, and experienced improvements in other markers of blood vessel health after receiving daily smartphone messages designed to cultivate ...
Apr 8, 2024
0
0
While the composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack
Apr 8, 2024
0
0
People with hypertension and obstructive sleep apnea were no less likely to see their blood pressure drop over six months if they used a mandibular advancement device (MAD), which is inserted onto the teeth similar to a bite ...
Apr 8, 2024
0
1
People with chronic chest pain who received a coronary sinus reducer (CSR)—a stent thought to increase the amount of oxygen-rich blood flowing to the heart muscle—experienced significant reductions in the daily number ...
Apr 8, 2024
0
2
Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with ...
Apr 8, 2024
0
0
The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with evidence of improvements in symptoms and exercise capacity among people with nonobstructive hypertrophic cardiomyopathy (HCM), ...
Apr 8, 2024
0
0
